Articles: chronic.
-
Cancer Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Inflammatory psedotumor of the lung is a rare, quasineoplastic lung tumor of unknown etiology. It occurs most often in young adults ⋯ Although pulmonary inflammatory pseudotumors are considered benign, they can be very aggressive locally or cause metastasis. The differential diagnosis is usually with lung cancer and the deffinitive diagnosis is made on histopathological exam. If possible, complete surgical resection is necessary and can cure the disease. Extended follow-up is required in these patients.Reference #1: Surgical management of pulmonary inflammatory pseudotumors: a single center experience. Mondello B, Lentini S, Barone M, Barresi P, Monaco F, Familiari D, La Rocca A, Sibilio M, Acri IE, David A, Monaco M. J Cardiothorac Surg. 2011 Feb 23;6:18. doi: 10.1186/1749-8090-6-18. PMID:21345228DISCLOSURE: The following authors have nothing to disclose: Ionela Belaconi, Claudia Toma, Stefan Dumitrache-Rujinski, Alina Croitoru, Miron BogdanNo Product/Research Disclosure Information.
-
Physiology/PFTs/Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Spirometry is recommended for the diagnosis of asthma and Chronic Obstructive Pulmonary Disease (COPD) in international guidelines and it may be useful for distinguishing asthma from COPD. Typically, the only data required for clinical decision making are the Forced Expiratory Volume in one second (FEV1) and the Forced Vital Capacity (FVC). Limitations of SIA promoted for adoption in primary care have been described [Can Fam Physician October 2011 57:1148-1152, 1153-1156.] This study examines how different SIA (one and two) may influence decision making among primary care physicians. ⋯ The following authors have nothing to disclose: Xiao Ou He, Anthony D'UrzoNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To outline the resource use and costs a U.S. health plan can anticipate during the evaluation and first year of treatment of a CTEPH patient ⋯ Vijay Joish: Employee: employee of bayer sponsor of study Christine Divers: Employee: employee of bayer sponsor of study Chakkarin CBurudpakdee: Consultant fee, speaker bureau, advisory committee, etc.: consultant of bayer sponsor of study Anshul Shah: Consultant fee, speaker bureau, advisory committee, etc.: consultant of bayer sponsor of study Stephen Mathai: Consultant fee, speaker bureau, advisory committee, etc.: consultant to bayer sponsor of studyNo Product/Research Disclosure Information.
-
Respiratory InfectionsSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: Community-acquired MRSA (CA-MRSA) pneumonia is an uncommon but potentially life-threatening disease. MRSA is generally not covered when treating CAP. Several small case series have described these patients. Certain clinical characteristics have been proposed that suggest MRSA as a pathogen. However, when to consider CA-MRSA is a subject of ongoing debate. The current study reviewed the risk factors, presentation, and outcomes of patients with CA-MRSA pneumonia in an urban community hospital. ⋯ The following authors have nothing to disclose: Kunal Patel, Viral Patel, Kelly Cervellione, Craig ThurmNo Product/Research Disclosure Information.
-
Pleural CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Sarcoidosis is a chronic multi-system disorder of unknown etiology characterized by granulomatous inflammation. Commonly involved organs include lymph nodes, lungs, skin, eyes and heart. Pulmonary involvement is manifested as hilar or mediastinal lymphadenopathy with parenchymal opacities. Pleural effusion and underlying pleural involvement with sarcoidosis is uncommon and is seen in less than 2% of the cases of pulmonary sarcoidosis. We present one of such case. ⋯ The following authors have nothing to disclose: Deepankar Sharma, Joshua RubenfeldNo Product/Research Disclosure Information.